446,866 Axon Enterprise, Inc $AXON Shares Purchased by Candriam S.C.A.

Candriam S.C.A. grew its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 6,980.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 453,268 shares of the biotechnology company’s stock after acquiring an additional 446,866 shares during the quarter. Axon Enterprise comprises 0.9% of Candriam S.C.A.’s portfolio, making the stock its 20th biggest position. Candriam S.C.A.’s holdings in Axon Enterprise were worth $191,515,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cullinan Associates Inc. increased its position in Axon Enterprise by 2,280.2% during the 3rd quarter. Cullinan Associates Inc. now owns 11,901 shares of the biotechnology company’s stock worth $5,028,000 after purchasing an additional 11,401 shares in the last quarter. Ethic Inc. raised its holdings in Axon Enterprise by 9,571.5% in the third quarter. Ethic Inc. now owns 618,108 shares of the biotechnology company’s stock valued at $261,163,000 after buying an additional 611,717 shares during the period. 180 Wealth Advisors LLC raised its holdings in Axon Enterprise by 202.8% in the third quarter. 180 Wealth Advisors LLC now owns 38,324 shares of the biotechnology company’s stock valued at $16,193,000 after buying an additional 25,669 shares during the period. StoneX Group Inc. lifted its position in Axon Enterprise by 3,123.1% during the third quarter. StoneX Group Inc. now owns 28,428 shares of the biotechnology company’s stock valued at $12,011,000 after buying an additional 27,546 shares in the last quarter. Finally, Verus Capital Partners LLC lifted its position in Axon Enterprise by 30.6% during the third quarter. Verus Capital Partners LLC now owns 584 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 137 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Isaiah Fields sold 1,017 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $480.45, for a total transaction of $488,617.65. Following the transaction, the insider directly owned 56,264 shares of the company’s stock, valued at approximately $27,032,038.80. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the completion of the transaction, the chief executive officer owned 3,118,012 shares of the company’s stock, valued at $1,587,036,927.88. This trade represents a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,397 shares of company stock worth $21,234,034 over the last three months. Insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $313.00 on Friday. The company has a market cap of $25.43 billion, a P/E ratio of 100.32, a PEG ratio of 5.95 and a beta of 1.48. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a one year low of $307.00 and a one year high of $665.07. The business’s 50-day simple moving average is $441.53 and its 200 day simple moving average is $475.20.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.89 by ($0.17). The company had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a return on equity of 3.95% and a net margin of 7.56%. The business’s revenue was up 27.8% on a year-over-year basis. During the same period last year, the firm posted $1.17 earnings per share. On average, sell-side analysts forecast that Axon Enterprise, Inc will post 2.10 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. UBS Group boosted their price objective on shares of Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research note on Tuesday. Craig Hallum lowered shares of Axon Enterprise from a “buy” rating to a “hold” rating and set a $390.00 target price on the stock. in a report on Friday. Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $735.00 to $615.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Northland Securities set a $540.00 price target on shares of Axon Enterprise in a research report on Friday. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $631.35.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.